Efficacy and safety of pegylated interferon fllfa-2a plus ribavirin for treatment of chronic hepatitis C and cirrhosis in Iranian

ABSTRACT

Background and aims: pegylation of Interferon prolongs the medication half-life, which has resulted in introducing Pegylated Interferon [PEG-IFN] as the new modality for treatment of chronic hepatitis C. This clinical trial was conducted to assess the efficacy and safety of Peg-INF in combination with ribavirin in a number of Iranian patients with chronic hepatitis C or cirrhosis